Mitsubishi UFJ Trust & Banking’s Intellia Therapeutics NTLA Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163K	Buy	+9,613	New	+$135K	﹤0.01%	1381

Other funds holding NTLA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's NTLA Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 9,613 shares worth $163K. The stake represents ﹤0.01% of the portfolio and ranks #1381 among its holdings.

130 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 9,613 shares of Intellia Therapeutics worth $163K as of Q2 2026.
Intellia Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1381 holding.
130 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.